The pharmacokinetics of gadodiamide in patients with severe renal insufficiency treated conservatively or undergoing hemodialysis or continuous ambulatory peritoneal dialysis.

摘要

In 1998, Academic Radiology published our study dealing with the pharmacokinetics of intravenously injected gadodiamide (Omniscan) in patients with either chronic kidney disease (CKD) stage 5 (glomerular filtration rate [GFR] <15 mL/min) and undergoing hemodialysis or being treated with continuous ambulatory peritoneal dialysis (CAPD) (1). The study was powered to access the classical parameters of pharmacokinetics as well as the dialyzability among our patients on hemo- or peritoneal dialysis. Contrast-induced nephropathy was also an important parameter. The conclusion was that gadodiamide could be used safely in the evaluated patient groups.